Based on our previous studies that oncolytic adenoviruses harboring sCAR-IL3 expression cassette successfully infected CD123+ leukemia cells, we proposed that engineering oncolytic adenoviruses to express sCAR-ligand fusion proteins may provide a universal strategy to redirect oncolytic adenoviruses to various membrane receptors on cancer cells resisting to Ad5 infection. The gene discussed is RPS4X; the disease is leukemia.